Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Novartis boasts a 26% net margin and a fortress balance sheet, while Teva's turnaround has returned it to profitability, but at what cost to stability?
Read the full articleYou might also wanna read
STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio
Novartis to pay $1.1B upfront for UK biotech Myricx to expand the pharma's ADC pipeline
Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a
Pharma companies' Q1 margins likely to decline despite revenue growth: Goldman Sachs
New Delhi [India], July 9 (ANI): Indian pharmaceutical companies are expected to report improved revenues in the first quarter of FY2026-27,
Top 3 Defense Stocks for 2026: RTX (RTX), Lockheed Martin (LMT), and AeroVironment (AVAV) Analysis
Explore three leading defense stocks for 2026: RTX (RTX), Lockheed Martin (LMT), and AeroVironment (AVAV) as military spending accelerates w
Doximity Inc (NYSE:DOCS) Passes Quality Investing Screen with Strong Profitability and Zero Debt
Doximity (DOCS) passes the Caviar quality screen with 177% ROIC, zero debt, and 32% EBIT growth outpacing revenue. A top-tier healthcare tec
STAT+: Compass says depression drug has long-lasting benefits
Vertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readout
Comments
Sign in to join the conversation.
No comments yet. Be the first.